Peptonic Medical AB (publ) ("Peptonic") announces the appointment of Daniel Rudeklint as interim CEO with immediate effect. Daniel Rudeklint replaces Anna Linton as CEO.
Daniel Rudeklint has been in Peptonic's board since January 2023 and has a strong financial background, very good insight into the company and solid experience in leading organizations. The work of recruiting a new permanent CEO is ongoing.
"On behalf of the board of directors, I thank Anna for the work she has done during the past years as CEO of Peptonic and how she has shown commitment and loyalty to the company," says Chairman of the board Anders Blom.
For further information, please contact:
Daniel Rudeklint, acting CEO, Peptonic Medical AB
Email: daniel.rudeklint@peptonicmedical.se
Phone: +46 73 158 02 73
About Peptonic Medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish Medical Device company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The Company is headquartered in Stockholm, Sweden, and operates a subsidiary, Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.